One of the most exciting developments in antiviral research has been the discovery of the
direct-acting antivirals (DAAs) that effectively cure chronic hepatitis C virus (HCV) infections …

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …

The hepatitis C virus (HCV) is an extremely diverse virus, subtypes of which are distributed
variably around the world. Viral genotypes may be divided into epidemic subtypes; those …

Abstract Background Hepatitis C virus (HCV) exhibits great genetic diversity and is classified
into 7 genotypes (GTs), with varied geographic prevalence. Until the recent development of …

Abstract Background Hepatitis C virus (HCV) is currently classified into 8 genotypes and 86
subtypes. The objective of this study was to characterize novel HCV subtypes and to …

Background & Aims HCV genotype, subtype, and presence of resistance-associated
substitutions (RASs) are key determinants for the selection of direct-acting antiviral (DAA) …

Background & Aims The fixed-dose combination of sofosbuvir/velpatasvir was highly
efficacious in patients infected with genotype (GT) 1–6 hepatitis C virus (HCV) in the …

Hepatitis B virus (HBV) infection is a major global health problem. Currently-available
therapies are ineffective in curing chronic HBV infection. HBV and its satellite hepatitis D …

It has been estimated by the World Health Organization (WHO) that over 71 million people
were infected with the hepatitis C virus (HCV) in 2015. Since then, a number of highly …

The global plan to eradicate hepatitis C virus (HCV) led by the World Health Organization
outlines the use of highly effective direct‐acting antiviral drugs (DAAs) to achieve elimination …